Search results
20 paź 2024 · Botulinum toxin A (BoNT-A) has been in clinical use for treating post-stroke spasticity for approximately 30 years and is the accepted standard of care for focal post-stroke spasticity (1).
- Treatment of adult spasticity with Botox (onabotulinumtoxinA ...
The Botox Economic Spasticity Trial (BEST) aimed to treat...
- Botulinum Toxin in Poststroke Spasticity - PMC - National Center for ...
The results of the reviewed studies of BTX treatment in...
- Treatment of adult spasticity with Botox (onabotulinumtoxinA ...
13 wrz 2012 · Lower extremity spasticity can limit ambulation, such as when an equinovarus foot prevents the foot flat position during the stance phase of gait, resulting in instability, and resulting in knee pain attributable to excessive recurvatum when ankle plantar flexor spasticity overwhelms.
The Botox Economic Spasticity Trial (BEST) aimed to treat patients in Europe and Canada with upper and/or lower limb post-stroke spasticity with onabotulinumtoxinA in a manner similar to clinical practice by using goal-oriented treatment (Goal Attainment Scaling).
The treatment of choice is botulinum toxin type A (BoNT-A) combined with adjuvant treatments. The temporary pharmacological effect implies periodic reassessment and reinjection. These long-term chronic programs require monitoring the functional impact of each cycle and the clinical evolution in relation to aging and repeated interventions. AIM.
10 lut 2024 · This article aims to provide a concise overview of the best available evidence for managing post-stroke spasticity. A modified scoping review, conducted following the PRISMA guidelines and the PRISMA Extension for Scoping Reviews (PRISMA-ScR), involved an intensive search on Medline and PubMed from 1 January 2000 to 31 August 2023.
The results of the reviewed studies of BTX treatment in poststroke upper and lower limb spasticity suggest that BTX injections safely and effectively decrease muscle tone and increase range of motion.
The use of BoNT-A and innovative techniques has facilitated a more individualized approach to treatment of post-stroke spasticity, which provides physicians with the opportunity to optimize outcomes and address multiple goals.
